Listed

Aptevo Therapeutics Inc.

APVONasdaqCIK 1671584HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$6.4m, Q2 FY2026
Net income−$6.4m, Q2 FY2026
Aptevo Therapeutics Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Cost of revenue$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Research and development$k3,887Research and development, Q3 FY2023, three months to 2023-09-30$3.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-07, accession 0000950170-24-122837.Report this figure3,591Research and development, Q4 FY2023, three months to 2023-12-31$3.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-02-14, accession 0000950170-25-020467. Derived: 12-month figure less the 9-month figure.Report this figure3,752Research and development, Q1 FY2024, three months to 2024-03-31$3.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-15, accession 0000950170-25-072622.Report this figure3,643Research and development, Q2 FY2024, three months to 2024-06-30$3.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-11, accession 0000950170-25-106247.Report this figure3,103Research and development, Q3 FY2024, three months to 2024-09-30$3.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-06, accession 0001193125-25-269598.Report this figure3,880Research and development, Q4 FY2024, three months to 2024-12-31$3.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-26, accession 0001193125-26-126278. Derived: 12-month figure less the 9-month figure.Report this figure3,633Research and development, Q1 FY2025, three months to 2025-03-31$3.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-13, accession 0001193125-26-221661.Report this figure3,328Research and development, Q2 FY2025, three months to 2025-06-30$3.3m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-14, accession 0001193125-26-350559.Report this figure4,044Research and development, Q3 FY2025, three months to 2025-09-30$4.0m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-06, accession 0001193125-25-269598.Report this figure3,535Research and development, Q4 FY2025, three months to 2025-12-31$3.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-26, accession 0001193125-26-126278. Derived: 12-month figure less the 9-month figure.Report this figure3,924Research and development, Q1 FY2026, three months to 2026-03-31$3.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-13, accession 0001193125-26-221661.Report this figure3,696Research and development, Q2 FY2026, three months to 2026-06-30$3.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-14, accession 0001193125-26-350559.Report this figure
Selling, general and administrative$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Operating income$k(6,561)Operating income, Q3 FY2023, three months to 2023-09-30−$6.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-07, accession 0000950170-24-122837.Report this figure(6,384)Operating income, Q4 FY2023, three months to 2023-12-31−$6.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-14, accession 0000950170-25-020467. Derived: 12-month figure less the 9-month figure.Report this figure(6,983)Operating income, Q1 FY2024, three months to 2024-03-31−$7.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-15, accession 0000950170-25-072622.Report this figure(6,024)Operating income, Q2 FY2024, three months to 2024-06-30−$6.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-11, accession 0000950170-25-106247.Report this figure(5,213)Operating income, Q3 FY2024, three months to 2024-09-30−$5.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269598.Report this figure(6,382)Operating income, Q4 FY2024, three months to 2024-12-31−$6.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-26, accession 0001193125-26-126278. Derived: 12-month figure less the 9-month figure.Report this figure(6,480)Operating income, Q1 FY2025, three months to 2025-03-31−$6.5m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-13, accession 0001193125-26-221661.Report this figure(6,226)Operating income, Q2 FY2025, three months to 2025-06-30−$6.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001193125-26-350559.Report this figure(7,610)Operating income, Q3 FY2025, three months to 2025-09-30−$7.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269598.Report this figure(5,996)Operating income, Q4 FY2025, three months to 2025-12-31−$6.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-26, accession 0001193125-26-126278. Derived: 12-month figure less the 9-month figure.Report this figure(6,837)Operating income, Q1 FY2026, three months to 2026-03-31−$6.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-13, accession 0001193125-26-221661.Report this figure(6,443)Operating income, Q2 FY2026, three months to 2026-06-30−$6.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001193125-26-350559.Report this figure
Income tax$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Net income$k(6,334)Net income, Q3 FY2023, three months to 2023-09-30−$6.3m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-07, accession 0000950170-24-122837.Report this figure(5,903)Net income, Q4 FY2023, three months to 2023-12-31−$5.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-14, accession 0000950170-25-020467. Derived: 12-month figure less the 9-month figure.Report this figure(6,834)Net income, Q1 FY2024, three months to 2024-03-31−$6.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269598.Report this figure(5,883)Net income, Q2 FY2024, three months to 2024-06-30−$5.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269598.Report this figure(5,101)Net income, Q3 FY2024, three months to 2024-09-30−$5.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269598.Report this figure(6,312)Net income, Q4 FY2024, three months to 2024-12-31−$6.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-26, accession 0001193125-26-126278. Derived: 12-month figure less the 9-month figure.Report this figure(6,408)Net income, Q1 FY2025, three months to 2025-03-31−$6.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001193125-26-350559.Report this figure(6,204)Net income, Q2 FY2025, three months to 2025-06-30−$6.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001193125-26-350559.Report this figure(7,549)Net income, Q3 FY2025, three months to 2025-09-30−$7.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001193125-25-269598.Report this figure(5,806)Net income, Q4 FY2025, three months to 2025-12-31−$5.8m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-26, accession 0001193125-26-126278. Derived: 12-month figure less the 9-month figure.Report this figure(6,697)Net income, Q1 FY2026, three months to 2026-03-31−$6.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001193125-26-350559.Report this figure(6,356)Net income, Q2 FY2026, three months to 2026-06-30−$6.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001193125-26-350559.Report this figure
Diluted EPS$ per share(22.16)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$22.16 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-07, accession 0000950170-24-122837.Report this figurenot reported(368.21)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$368.21 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-15, accession 0000950170-25-072622.Report this figure(1236.96)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$1236.96 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-11, accession 0000950170-25-106247.Report this figure(357.86)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$357.86 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001193125-25-269598.Report this figurenot reported(1581.81)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$1581.81 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-13, accession 0001193125-26-221661.Report this figure(151.29)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$151.29 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001193125-26-350559.Report this figure(2.23)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$2.23 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001193125-25-269598.Report this figurenot reported(6.41)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$6.41 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-13, accession 0001193125-26-221661.Report this figure(5.31)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$5.31 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001193125-26-350559.Report this figure
Basic EPS$ per share(22.16)Basic EPS, Q3 FY2023, three months to 2023-09-30−$22.16 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-07, accession 0000950170-24-122837.Report this figurenot reported(368.21)Basic EPS, Q1 FY2024, three months to 2024-03-31−$368.21 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-15, accession 0000950170-25-072622.Report this figure(1236.96)Basic EPS, Q2 FY2024, three months to 2024-06-30−$1236.96 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-11, accession 0000950170-25-106247.Report this figure(357.86)Basic EPS, Q3 FY2024, three months to 2024-09-30−$357.86 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-06, accession 0001193125-25-269598.Report this figurenot reported(1581.81)Basic EPS, Q1 FY2025, three months to 2025-03-31−$1581.81 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-13, accession 0001193125-26-221661.Report this figure(151.29)Basic EPS, Q2 FY2025, three months to 2025-06-30−$151.29 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-14, accession 0001193125-26-350559.Report this figure(2.23)Basic EPS, Q3 FY2025, three months to 2025-09-30−$2.23 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-06, accession 0001193125-25-269598.Report this figurenot reported(6.41)Basic EPS, Q1 FY2026, three months to 2026-03-31−$6.41 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-13, accession 0001193125-26-221661.Report this figure(5.31)Basic EPS, Q2 FY2026, three months to 2026-06-30−$5.31 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-14, accession 0001193125-26-350559.Report this figure

Balance sheet

Cash and equivalents$9.8m, Q2 FY2026
Long-term debt$0, FY2023
Shareholders' equity$6.0m, Q2 FY2026
Aptevo Therapeutics Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m19.1Cash and equivalents, Q3 FY2023, at 2023-09-30$19.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-14, accession 0000950170-23-063379.Report this figure16.9Cash and equivalents, FY2023, at 2023-12-31$16.9m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2025-02-14, accession 0000950170-25-020467.Report this figure10.3Cash and equivalents, Q1 FY2024, at 2024-03-31$10.3m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-15, accession 0000950170-25-072622.Report this figure8.1Cash and equivalents, Q2 FY2024, at 2024-06-30$8.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-11, accession 0000950170-25-106247.Report this figure7.8Cash and equivalents, Q3 FY2024, at 2024-09-30$7.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-06, accession 0001193125-25-269598.Report this figure8.7Cash and equivalents, FY2024, at 2024-12-31$8.7m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-26, accession 0001193125-26-126278.Report this figure2.1Cash and equivalents, Q1 FY2025, at 2025-03-31$2.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-13, accession 0001193125-26-221661.Report this figure9.4Cash and equivalents, Q2 FY2025, at 2025-06-30$9.4m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-14, accession 0001193125-26-350559.Report this figure21.1Cash and equivalents, Q3 FY2025, at 2025-09-30$21.1m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-06, accession 0001193125-25-269598.Report this figure21.6Cash and equivalents, FY2025, at 2025-12-31$21.6m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-14, accession 0001193125-26-350559.Report this figure14.5Cash and equivalents, Q1 FY2026, at 2026-03-31$14.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-13, accession 0001193125-26-221661.Report this figure9.8Cash and equivalents, Q2 FY2026, at 2026-06-30$9.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-14, accession 0001193125-26-350559.Report this figure
Current assets$m21.1Current assets, Q3 FY2023, at 2023-09-30$21.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-14, accession 0000950170-23-063379.Report this figure19.1Current assets, FY2023, at 2023-12-31$19.1m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-02-14, accession 0000950170-25-020467.Report this figure12.1Current assets, Q1 FY2024, at 2024-03-31$12.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-08, accession 0000950170-24-055096.Report this figure9.6Current assets, Q2 FY2024, at 2024-06-30$9.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-08, accession 0000950170-24-093366.Report this figure10.0Current assets, Q3 FY2024, at 2024-09-30$10.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-07, accession 0000950170-24-122837.Report this figure10.7Current assets, FY2024, at 2024-12-31$10.7m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-26, accession 0001193125-26-126278.Report this figure3.6Current assets, Q1 FY2025, at 2025-03-31$3.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-15, accession 0000950170-25-072622.Report this figure11.1Current assets, Q2 FY2025, at 2025-06-30$11.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-11, accession 0000950170-25-106247.Report this figure22.6Current assets, Q3 FY2025, at 2025-09-30$22.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-06, accession 0001193125-25-269598.Report this figure23.1Current assets, FY2025, at 2025-12-31$23.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-14, accession 0001193125-26-350559.Report this figure16.0Current assets, Q1 FY2026, at 2026-03-31$16.0m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-13, accession 0001193125-26-221661.Report this figure10.8Current assets, Q2 FY2026, at 2026-06-30$10.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-14, accession 0001193125-26-350559.Report this figure
Total assets$m27.1Total assets, Q3 FY2023, at 2023-09-30$27.1m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-14, accession 0000950170-23-063379.Report this figure24.8Total assets, FY2023, at 2023-12-31$24.8m. XBRL concept us-gaap:Assets. 10-K filed 2025-02-14, accession 0000950170-25-020467.Report this figure17.6Total assets, Q1 FY2024, at 2024-03-31$17.6m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-08, accession 0000950170-24-055096.Report this figure14.9Total assets, Q2 FY2024, at 2024-06-30$14.9m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-08, accession 0000950170-24-093366.Report this figure15.1Total assets, Q3 FY2024, at 2024-09-30$15.1m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-07, accession 0000950170-24-122837.Report this figure15.6Total assets, FY2024, at 2024-12-31$15.6m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-26, accession 0001193125-26-126278.Report this figure8.3Total assets, Q1 FY2025, at 2025-03-31$8.3m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-15, accession 0000950170-25-072622.Report this figure15.6Total assets, Q2 FY2025, at 2025-06-30$15.6m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-11, accession 0000950170-25-106247.Report this figure27.0Total assets, Q3 FY2025, at 2025-09-30$27.0m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-06, accession 0001193125-25-269598.Report this figure27.2Total assets, FY2025, at 2025-12-31$27.2m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-14, accession 0001193125-26-350559.Report this figure19.9Total assets, Q1 FY2026, at 2026-03-31$19.9m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-13, accession 0001193125-26-221661.Report this figure14.5Total assets, Q2 FY2026, at 2026-06-30$14.5m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-14, accession 0001193125-26-350559.Report this figure
Current liabilities$m6.8Current liabilities, Q3 FY2023, at 2023-09-30$6.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-14, accession 0000950170-23-063379.Report this figure7.2Current liabilities, FY2023, at 2023-12-31$7.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-02-14, accession 0000950170-25-020467.Report this figure6.3Current liabilities, Q1 FY2024, at 2024-03-31$6.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-08, accession 0000950170-24-055096.Report this figure5.4Current liabilities, Q2 FY2024, at 2024-06-30$5.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-08, accession 0000950170-24-093366.Report this figure5.9Current liabilities, Q3 FY2024, at 2024-09-30$5.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-07, accession 0000950170-24-122837.Report this figure6.2Current liabilities, FY2024, at 2024-12-31$6.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-26, accession 0001193125-26-126278.Report this figure5.4Current liabilities, Q1 FY2025, at 2025-03-31$5.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-15, accession 0000950170-25-072622.Report this figure4.9Current liabilities, Q2 FY2025, at 2025-06-30$4.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-11, accession 0000950170-25-106247.Report this figure5.6Current liabilities, Q3 FY2025, at 2025-09-30$5.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-06, accession 0001193125-25-269598.Report this figure6.1Current liabilities, FY2025, at 2025-12-31$6.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-14, accession 0001193125-26-350559.Report this figure4.8Current liabilities, Q1 FY2026, at 2026-03-31$4.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-13, accession 0001193125-26-221661.Report this figure5.2Current liabilities, Q2 FY2026, at 2026-06-30$5.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-14, accession 0001193125-26-350559.Report this figure
Total liabilities$m12.4Total liabilities, Q3 FY2023, at 2023-09-30$12.4m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-14, accession 0000950170-23-063379.Report this figure12.6Total liabilities, FY2023, at 2023-12-31$12.6m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-02-14, accession 0000950170-25-020467.Report this figure11.5Total liabilities, Q1 FY2024, at 2024-03-31$11.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-08, accession 0000950170-24-055096.Report this figure10.5Total liabilities, Q2 FY2024, at 2024-06-30$10.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-08, accession 0000950170-24-093366.Report this figure10.7Total liabilities, Q3 FY2024, at 2024-09-30$10.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-07, accession 0000950170-24-122837.Report this figure10.8Total liabilities, FY2024, at 2024-12-31$10.8m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-26, accession 0001193125-26-126278.Report this figure9.8Total liabilities, Q1 FY2025, at 2025-03-31$9.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-15, accession 0000950170-25-072622.Report this figure9.1Total liabilities, Q2 FY2025, at 2025-06-30$9.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-11, accession 0000950170-25-106247.Report this figure9.6Total liabilities, Q3 FY2025, at 2025-09-30$9.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-06, accession 0001193125-25-269598.Report this figure9.8Total liabilities, FY2025, at 2025-12-31$9.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-14, accession 0001193125-26-350559.Report this figure8.3Total liabilities, Q1 FY2026, at 2026-03-31$8.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-13, accession 0001193125-26-221661.Report this figure8.5Total liabilities, Q2 FY2026, at 2026-06-30$8.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-14, accession 0001193125-26-350559.Report this figure
Long-term debt$m0.0Long-term debt, Q3 FY2023, at 2023-09-30$0. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2023-11-14, accession 0000950170-23-063379.Report this figure0.0Long-term debt, FY2023, at 2023-12-31$0. XBRL concept us-gaap:LongTermDebt. 10-K filed 2024-03-05, accession 0000950170-24-025428.Report this figurenot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Current portion of debt$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Shareholders' equity$m14.7Shareholders' equity, Q3 FY2023, at 2023-09-30$14.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-07, accession 0000950170-24-122837.Report this figure12.2Shareholders' equity, FY2023, at 2023-12-31$12.2m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-26, accession 0001193125-26-126278.Report this figure6.1Shareholders' equity, Q1 FY2024, at 2024-03-31$6.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001193125-25-269598.Report this figure4.5Shareholders' equity, Q2 FY2024, at 2024-06-30$4.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001193125-25-269598.Report this figure4.4Shareholders' equity, Q3 FY2024, at 2024-09-30$4.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001193125-25-269598.Report this figure4.8Shareholders' equity, FY2024, at 2024-12-31$4.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001193125-26-350559.Report this figure(1.5)Shareholders' equity, Q1 FY2025, at 2025-03-31−$1.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001193125-26-350559.Report this figure6.5Shareholders' equity, Q2 FY2025, at 2025-06-30$6.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001193125-26-350559.Report this figure17.4Shareholders' equity, Q3 FY2025, at 2025-09-30$17.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-06, accession 0001193125-25-269598.Report this figure17.4Shareholders' equity, FY2025, at 2025-12-31$17.4m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001193125-26-350559.Report this figure11.6Shareholders' equity, Q1 FY2026, at 2026-03-31$11.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001193125-26-350559.Report this figure6.0Shareholders' equity, Q2 FY2026, at 2026-06-30$6.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001193125-26-350559.Report this figure

Cash flow

Operating cash flow−$5.5m, Q2 FY2026
Aptevo Therapeutics Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$k(6,240)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$6.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-07, accession 0000950170-24-122837. Derived: 9-month figure less the 6-month figure.Report this figure(5,253)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$5.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-14, accession 0000950170-25-020467. Derived: 12-month figure less the 9-month figure.Report this figure(6,651)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$6.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-15, accession 0000950170-25-072622.Report this figure(6,153)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$6.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-11, accession 0000950170-25-106247. Derived: 6-month figure less the 3-month figure.Report this figure(5,222)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$5.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001193125-25-269598. Derived: 9-month figure less the 6-month figure.Report this figure(5,759)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$5.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-26, accession 0001193125-26-126278. Derived: 12-month figure less the 9-month figure.Report this figure(6,575)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$6.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-13, accession 0001193125-26-221661.Report this figure(7,093)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$7.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001193125-26-350559. Derived: 6-month figure less the 3-month figure.Report this figure(6,688)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$6.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001193125-25-269598. Derived: 9-month figure less the 6-month figure.Report this figure(5,236)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$5.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-26, accession 0001193125-26-126278. Derived: 12-month figure less the 9-month figure.Report this figure(7,965)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$8.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-13, accession 0001193125-26-221661.Report this figure(5,454)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$5.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001193125-26-350559. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$knot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported

Shares

Diluted shares (weighted)1.20m, Q2 FY2026
Aptevo Therapeutics Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)k shares5,091Diluted shares (weighted), Q3 FY2022, three months to 2022-09-305,090,592 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-14, accession 0000950170-23-063379.Report this figure160Diluted shares (weighted), Q1 FY2023, three months to 2023-03-31159,597 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-08, accession 0000950170-24-055096.Report this figure147Diluted shares (weighted), Q2 FY2023, three months to 2023-06-30147,321 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-08, accession 0000950170-24-093366.Report this figure286Diluted shares (weighted), Q3 FY2023, three months to 2023-09-30285,886 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-07, accession 0000950170-24-122837.Report this figure18.6Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3118,560 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-15, accession 0000950170-25-072622.Report this figure4.8Diluted shares (weighted), Q2 FY2024, three months to 2024-06-304,756 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-11, accession 0000950170-25-106247.Report this figure14.3Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3014,254 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-06, accession 0001193125-25-269598.Report this figure4.1Diluted shares (weighted), Q1 FY2025, three months to 2025-03-314,051 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-13, accession 0001193125-26-221661.Report this figure41.0Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3041,008 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-14, accession 0001193125-26-350559.Report this figure4,049Diluted shares (weighted), Q3 FY2025, three months to 2025-09-304,049,046 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-06, accession 0001193125-25-269598.Report this figure1,061Diluted shares (weighted), Q1 FY2026, three months to 2026-03-311,060,678 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-13, accession 0001193125-26-221661.Report this figure1,196Diluted shares (weighted), Q2 FY2026, three months to 2026-06-301,196,364 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-14, accession 0001193125-26-350559.Report this figure

Shares outstanding: 1.80mShares outstanding, period not labelled, at 2026-08-141,801,970 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-14, accession 0001193125-26-350559.Report this figure at Aug 14, 2026, from the cover of the 10-Q filed Aug 14, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. Listed shows no prices and gives no investment advice.